Boehringer's Spiriva/Micardis remarkably grew up.

Boehringer Ingelheim achieved 22% sales up during the first half of this year at 4.5 billion Euro dollars (5,700 billion won), thank to the new AIDS drug, Aptivus, a COPD therapeutic drug (Spririva) and a new anti-hypertension drug (Micardis). The operating incomes recorded 768 million Euro dollars (970 billion won).

Such sales growth was made largely by 80% with the prescription drugs incl...